Business
Medicure announces an agreement with Reliance Life Sciences for the marketing rights of a cardiovascular biosimilar
Medicure announces an agreement with Reliance Life Sciences for the marketing rights of a...
About this update from Medicure Inc.
[{"type":"text","content":"Medicure-AgrmntRelian\n \n \n \n Medicure announces an agreement with Reliance Life Sciences for the marketing rights of a cardiovascular biosimilar\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n WINNIPEG, AB, Oct. 5, 2020\n \n \n \n \n \n WINNIPEG\n \n , AB,\n \n Oct. 5, 2020\n \n /CNW/ - Medicure Inc. (\"Medicure\" or the \"Company\") (TSXV: MPH) (OTC: MCUJF), a pharmaceutical company, announces that through its wholly-owned subsidiary, Medicure International Inc., it has entered into a License, Manufacture and Supply Agreement (the \"Agreement\") with Reliance Life Sciences Private Limited (\"RLS\") for a cardiovascular biosimilar (the \"Product\"). Medicure is responsible for the regulatory approval process for the Product. A biosimilar is a biological product that is highly similar to and has no clinically meaningful differences from an approved reference product. The Agreement grants an exclusive right to Medicure to market and sell the Product in\n \n the United States of America\n \n ,\n \n Canada\n \n and the European Union.\n \n \n \"We are very pleased with the agreement we have reached with RLS. The Product fits well with Medicure's mission of being a significant cardiovascular company focused on the U.S. market.\" commented Dr.\n \n Albert Friesen\n \n , Chief Executive Officer for Medicure. \"We look forward to the growth of our portfolio of cardiovascular products.\"\n \n \n \n About Medicure Inc.\n \n \n Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the Company is the marketing and distribution of AGGRASTAT\n \n ®\n \n (tirofiban hydrochloride) injection and ZYPITAMAG\n \n TM\n \n (pitavastatin) tablets in\n \n the United States\n \n , where they are sold through the Company's U.S. subsidiary, Medicure Pharma Inc. For more information on Medicure please visit\n \n www.medicure.com\n \n . For additional information about ZYPITAMAG\n \n TM\n \n , refer to the full\n \n Prescribing Information\n \n .\n \...